IMS 2023 | Session highlights: managing the aging population in myeloma & promising treatment options
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, gives an overview of a session held at this year’s meeting which focused on treating elderly or frail patients with relapsed/refractory multiple myeloma (RRMM), starting with the role of next-generation antibodies such as isatuximab and elotuzumab. Dr Richardson also highlights the encouraging outcomes observed with the combination of pomalidomide and bortezomib, as well as antibody-drug conjugates (ADCs) such as belantamab mafodotin. Following this, Dr Richardson discusses the mechanism of action of other novel therapeutics, including melflufen, a peptide-drug conjugate, selinexor, an XPO1 inhibitor, and the novel CELMoDs iberdomide and mezigdomide. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting: Oncopeptides, Celgene/BMS, Karyopharm, Sanofi, GSK
Research grant: Oncopeptides, Celgene/BMS, Karopharm, Takeda
